Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EPS (Basic) (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed EPS (Basic) for 6 consecutive years, with -$0.74 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 67.83% to -$0.74 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.64 through Dec 2025, up 65.62% year-over-year, with the annual reading at -$1.65 for FY2025, 64.59% up from the prior year.
  • EPS (Basic) hit -$0.74 in Q4 2025 for Insight Molecular Diagnostics, down from -$0.34 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.82 in Q1 2023 to a low of -$8.03 in Q4 2022.
  • Historically, EPS (Basic) has averaged -$1.01 across 5 years, with a median of -$0.38 in 2021.
  • Biggest five-year swings in EPS (Basic): tumbled 1907.5% in 2022 and later skyrocketed 2150.0% in 2023.
  • Year by year, EPS (Basic) stood at -$0.4 in 2021, then crashed by 1907.5% to -$8.03 in 2022, then skyrocketed by 74.22% to -$2.07 in 2023, then fell by 11.11% to -$2.3 in 2024, then skyrocketed by 67.83% to -$0.74 in 2025.
  • Business Quant data shows EPS (Basic) for IMDX at -$0.74 in Q4 2025, -$0.34 in Q3 2025, and -$0.3 in Q2 2025.